Department of Cardiac Surgery, University Hospital Basel, Basel, Switzerland.
Mediators Inflamm. 2019 Dec 4;2019:5648051. doi: 10.1155/2019/5648051. eCollection 2019.
Single-dose cardioplegia is preferred in minimal invasive mitral valve surgery to maintain the adjustment of the operative site without change of preset visualization. The aim of our study was to compare two widely used crystalloid cardioplegias Bretschneider (Custodiol®) versus St. Thomas 2 in patients who underwent mitral valve repair via small anterolateral right thoracotomy.
From May 2012 until February 2019, 184 isolated mitral valve procedures for mitral valve repair via anterolateral right thoracotomy were performed using Bretschneider (Custodiol®) cardioplegia ( = 123) or St. Thomas ( = 61). Primary efficacy endpoint was peak postoperative high-sensitivity cardiac troponin (hs-cTnT) during hospitalization. Secondary endpoints were peak creatine kinase-muscle brain type (CK-MB) and creatine kinase (CK) as well as safety outcomes. We used inverse probability of treatment weighting (IPTW) in order to adjust for confounding by indication.
Peak hs-cTnT was higher after use of Bretschneider (Custodiol®) (geometric mean 716 mg/L, 95% confidence interval (CI) 605-847 mg/L) vs. St. Thomas 2 (561 mg/L, CI 467-674 mg/L, = 0.047). Peak CK-MB (geometric mean after Bretschneider (Custodiol®): 40 g/L, CI 35-46, St. Thomas 2: 33 g/L, CI 27-41, = 0.295) and CK (geometric mean after Bretschneider (Custodiol®): 1370 U/L, CI 1222-1536, St. Thomas 2: 1152 U/L, CI 972-1366, = 0.037) showed the same pattern. We did not see any difference with respect to postoperative complications between treatment groups after IPTW.
Use of St. Thomas 2 cardioplegia was associated with lower postoperative peak levels of all cardiac markers that reflect cardiac ischemia such as hs-cTnT, CK, and CK-MB as compared to Bretschneider (Custodiol®) in propensity-weighted treatment groups.
在微创二尖瓣手术中,单次剂量心脏停搏液是首选,以保持手术部位的调整,而无需改变预设的可视化效果。我们的研究目的是比较两种广泛使用的晶体心脏停搏液布雷施奈德(Custodiol®)与托马斯 2 号在通过小前外侧右胸切开术行二尖瓣修复的患者中的应用。
2012 年 5 月至 2019 年 2 月,184 例通过右前外侧小切口行二尖瓣修复的孤立性二尖瓣手术采用布雷施奈德(Custodiol®)心脏停搏液(=123 例)或托马斯 2 号(=61 例)进行。主要疗效终点是住院期间术后高峰高敏肌钙蛋白(hs-cTnT)。次要终点是肌酸激酶同工酶(CK-MB)和肌酸激酶(CK)的峰值以及安全性结果。我们使用逆概率治疗加权(IPTW)来调整适应证引起的混杂因素。
使用布雷施奈德(Custodiol®)时,hs-cTnT 的峰值更高(几何均数 716mg/L,95%置信区间[CI]605-847mg/L)vs. 托马斯 2 号(561mg/L,CI 467-674mg/L,=0.047)。CK-MB 的峰值(布雷施奈德(Custodiol®)后几何均数:40g/L,CI 35-46,托马斯 2 号:33g/L,CI 27-41,=0.295)和 CK 的峰值(布雷施奈德(Custodiol®)后几何均数:1370U/L,CI 1222-1536,托马斯 2 号:1152U/L,CI 972-1366,=0.037)也呈现相同的模式。在 IPTW 后的治疗组中,我们没有看到术后并发症方面的任何差异。
与布雷施奈德(Custodiol®)相比,在倾向评分治疗组中,使用托马斯 2 号心脏停搏液与术后 hs-cTnT、CK 和 CK-MB 等反映心肌缺血的所有心肌标志物的峰值水平较低相关。